Macquarie Group LTD Editas Medicine, Inc. Transaction History

Macquarie Group LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $9,326 - $14,895	-767 Reduced 39.19%	1,190 $24,000
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $10,075 - $18,238	322 Added 19.69%	1,957 $111,000
Q1 2021 May 14, 2021	SELL	$39.71 - $90.58 $19,934 - $45,471	-502 Reduced 23.49%	1,635 $69,000
Q2 2020 Aug 11, 2020	BUY	$18.5 - $34.34 $39,534 - $73,384	2,137 New	2,137 $63,000
Q3 2018 Nov 15, 2018	SELL	$27.65 - $38.39 $11,060 - $15,356	-400 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $12,560 - $16,404	400 New	400 $14,000
Q1 2018 May 11, 2018	SELL	$29.84 - $44.08 $77,584 - $114,608	-2,600 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$21.89 - $31.34 $56,914 - $81,484	2,600	2,600 $80,000

240

56.5M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $85.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.